GIPC2

Across TCGA pan-cancer cohorts, GIPC2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GIPC2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GIPC2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GIPC2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where GIPC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.830	0.435	.005	49	view →
COAD	DFS	Median	All	1.000	0.888	.023	42	view →
PDAC	DFS	Tertile	All	0.547	0.316	<.001	26	view →
LUAD	DFS	Quartile	All	0.854	0.466	.001	18	view →
LSCC	OS	Tertile	II,III,IV	0.607	1.000	.009	15	view →
HNSC	DFS	Quartile	IV	1.000	0.657	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GIPC2–CCRCC (OS)

Open the CCRCC breakdown →